
Please try another search
TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company’s products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of selenium deficiency; and focuses on development of the nodal diagnostic devices and anti-body drugs. TaiRx, Inc. was founded in 2011 and is based in Taipei City, Taiwan.
Name | Age | Since | Title |
---|---|---|---|
Sheng-Chu Kuo | - | - | Director |
Jang-Yang Chang | - | - | Member of Scientific Advisory Committee |
Andrew Lin | - | - | Chairman of The Board |
Sarah Lee | - | - | Director |
Lucas Lin | - | - | Independent Director |
Yi-Wen Chu | - | - | Senior VP & Director |
Mary J.C. Hendrix | - | - | Member of Scientific Advisory Committee |
Tian-Shung Wu | - | - | Director |
Hsien-Shou Kuo | - | - | Independent Director |
Chia Hsiang Chang | - | - | Independent Director |
Harry M. Olson | - | - | Member of Scientific Advisory Committee |
Chien Du-Shieng | - | - | Co-Founder, President, CEO & Director |
Frank Shen Hua | - | - | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review